세계의 바이오소재 시장 규모는 2024년에 1,261억 달러에 달했습니다. 향후 IMARC Group은 시장이 2033년까지 2,897억 달러에 달하며, 2025-2033년에 9.7%의 성장률(CAGR)을 보일 것으로 예측하고 있습니다. 헬스케어 산업에서의 지속적 진보가 심혈관질환의 유병률 상승과 함께 주로 시장을 촉진하고 있습니다.
3D 프린팅 기술 개발
3D 프린팅 기술을 비롯한 새로운 혁신 기술의 도입으로 의료용 임플란트 및 장비의 설계 및 제조 방법이 개선되고 있습니다. 또한 기존 방법으로는 어렵거나 불가능했던 환자 고유의 복잡한 형상을 제조할 수 있게 되었습니다. 그 결과, 이러한 기술은 치과, 정형외과, 보철 등 해부학적 정밀도가 중요한 분야에 광범위하게 적용되고 있습니다. 이것이 유리한 바이오소재 시장의 최근 비즈니스 기회 중 하나가 되고 있습니다. 예를 들어 2024년 2월, Nanavati Max Super Specialty Hospital은 뭄바이에 의료용 3D 프린팅 실험실을 개설하여 고정밀 수술을 용이하게 했습니다. 이 선구적인 시설은 종양학과 긴밀하게 통합되어 재건 정형외과, 종양학, 특수 치과 수술에서 정확하고 신중하게 수행해야 하는 최첨단 정밀 수술을 제공합니다. 또한 바이오소재 분야에서는 개별 환자의 해부학적 구조에 맞는 맞춤형 복잡한 의료기기 및 임플란트를 제작하기 위한 3D 프린팅 기술이 광범위하게 통합되어 전 세계에서 더욱 폭넓은 지지를 얻고 있습니다. 예를 들어 2023년 10월, 베르겐 하우켈란 대학병원의 작업치료사들은 3D 프린팅과 스캐닝 기술을 사용하여 통증 감소, 기능 저하 최소화, 환자 순응도 향상 등을 실현하는 개인 맞춤형 손 보조기 개발을 지원하는 연구를 발표했습니다. 이와는 별도로, 3D 프린팅은 기계적 특성이 다른 재료의 경사면을 통합할 수 있으며, 이 또한 시장에 긍정적인 영향을 미치고 있습니다. 예를 들어 2023년 10월, 에보닉은 다양한 의료용 임플란트 등급 필라멘트와 탄소섬유 강화 PEEK를 출시했습니다. 또한 이러한 기술은 만성질환의 치료를 지원하며 향후 수년간 전체 바이오소재 시장 전망을 강화할 것으로 예측됩니다. 예를 들어 2023년 7월에는 한국생명공학연구원(Korea Research Institute of Bioscience and Biotechnology), 한국기계연구원(Korea Institute of Machinery and Materials), 과학기술정보통신부(Ministry of Science and ICT) 소관 연구소와 공동연구를 통해 세계 최초로 자연살해(NK) 면역세포의 기능을 강화하는 3D 바이오프린팅 기술이 발표되었습니다.
조직공학의 혁신
조직공학은 연구에서 중요한 역할을 하고 있습니다. 조직 기능을 유지, 회복, 개선하기 위한 생물학적 대체물 개발에서 큰 인기를 얻고 있습니다. 예를 들어 OrganaBio는 2023년 6월 재생의료와 세포치료의 진보를 가속화하기 위해 특별히 설계된 NeoPAC 태반과 탯줄 조직을 도입한다고 발표했습니다. 또한 OrganaBio는 연구용(RUO)과 임상용 조직을 모두 제공함으로써 연구자들이 출생 조직의 잠재력을 이끌어내어 많은 질병을 치료할 수 있는 혁신적인 치료법을 개발할 수 있도록 장려하고 있습니다. 이와는 별도로, 새로운 조직의 형성을 촉진하기 위해 바람직한 세포 간 상호 작용을 유발하도록 설계된 재료인 새로운 스캐폴딩에 대한 수요 증가도 시장을 상승시키고 있습니다. 예를 들어 2023년 6월, 조직 공학의 주요 혁신 기업 중 하나인 3DBioFibR은 CollaFibR 3D와 μCollaFibR 스캐폴더라는 두 가지 새로운 콜라겐 섬유 제품을 출시했습니다. 이 제품들은 조직 배양 및 조직 공학 용도에 큰 이점을 제공합니다. 또한 보다 구조적, 기능적으로 정확한 조직공학을 가능하게 하기 위해 다양한 조직들의 연구개발 활동과 연구시설에 대한 투자가 증가하면서 조사 키워드 시장의 매출에 기여하고 있습니다. 예를 들어 2023년 1월, National Institute of Biomedical Imaging and Bioengineering(NIBIB)은 첨단 기술의 검증, 개발 및 보급을 가속화하기 위한 새로운 교내 연구 프로그램인 Center for Biomedical Engineering Technology Acceleration(BETA 센터)을 설립했습니다. 이 센터는 바이오센싱, 인공/합성생물학, 바이오메디컬 이미징, 나노소재, 바이오소재 등 여러 분야에 초점을 맞추었습니다.
상처 드레싱의 용도 확대
바이오소재는 급성 및 만성 부상을 포함한 다양한 유형의 상처의 치유 과정과 치료 결과를 개선하는 데 도움이 되므로 첨단 상처 드레싱에 대한 채택이 증가하고 있으며, 이는 중요한 성장 촉진요인으로 작용하고 있습니다. 이 외에도 주요 기업은 지속가능한 상처 치료용 재료를 개발하고 있습니다. 예를 들어 2024년 3월, 과학기술부 산하 고등과학기술연구소(IASST)의 과학자 팀은 바나나 섬유로 만든 친환경 상처 드레싱을 발표했습니다. 또한 이 혁신적인 드레싱 재료의 제조에 사용되는 재료는 모두 현지에서 구할 수 있는 천연 재료이기 때문에 제조 공정은 비용 효율적이고 간단하며 무해합니다. 이와는 별도로 바이오소재 기반 상처 드레싱에 대한 선호도가 높아지면서 바이오소재 시장 가격이 상승하고 있습니다. 상처 드레싱은 폼, 하이드로겔, 필름 등 다양한 재료로 제조되며, 항균제와 같은 생물학적 활성 물질을 함유하고 있으며, 감염을 줄이고 조직 재생을 촉진하는 경우가 많습니다. 예를 들어 2022년 5월 스웨덴의 의료기기 스타트업 기업인 Amferia AB는 양친매성 항균 하이드로겔을 기반으로 한 항균 물질에 대해 미국 특허청(USPTO)으로부터 기초 특허를 부여받았습니다. 이와 함께 2023년 6월 Journal of Biomaterials Advances에 게재된 연구 결과에 따르면 Belfast의 Queen's University 연구팀은 비계라고도 불리는 3D 프린팅 붕대를 디자인하여 당뇨병성 족부궤양(DFU)을 치료하는 획기적인 치료법을 제시했습니다. 획기적인 치료 방법을 제시했습니다.
The global biomaterials market size reached USD 126.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 289.7 Billion by 2033, exhibiting a growth rate (CAGR) of 9.7% during 2025-2033. Continuous advancements in the healthcare industry, along with the rising prevalence of cardiovascular diseases, are primarily propelling the market.
Development of 3D Printing Technologies
The introduction of novel innovations, including 3D printing technologies, is improving the ways in which medical implants and devices are designed and manufactured. Moreover, they enable the production of patient-specific and complex shapes that are difficult or impossible to achieve with traditional methods. Consequently, these technologies find extensive applications in fields, such as dentistry, orthopedics, prosthetics, etc., where anatomical precision is crucial. This, in turn, is one of the lucrative biomaterials market recent opportunities. For example, in February 2024, Nanavati Max Super Specialty Hospital launched a medical 3D printing laboratory in Mumbai to facilitate high-precision surgeries. This pioneering facility is closely integrated with oncology to offer state-of-the-art precision surgeries that are required to be performed accurately and carefully in reconstructive orthopedic, oncologic, and specialized dentistry surgeries. Additionally, the widespread integration of 3D printing technology in biomaterials for creating customized and complex medical devices and implants tailored to individual patients' anatomies is further gaining extensive traction across the globe. For instance, in October 2023, a study was published that assisted the occupational therapists at the Haukeland University Hospital in Bergen to develop personalized hand orthoses by using 3D printing and scanning technologies, which can reduce pain, minimize deterioration, enhance patient compliance, etc. Apart from this, 3D printing allows for the incorporation of gradients of materials with varying mechanical properties, which is also positively influencing the market. For example, in October 2023, Evonik launched implant-grade filaments and carbon-fiber-reinforced PEEK for numerous medical applications. Furthermore, these technologies assist in the treatment of chronic diseases, which is projected to fuel the overall biomaterials market outlook in the coming years. For example, in July 2023, through joint research with the Korea Research Institute of Bioscience and Biotechnology, the Korea Institute of Machinery and Materials, and the institute under the jurisdiction of the Ministry of Science and ICT launched the world's first 3D bioprinting technology that enhances the function of natural killer (NK) immune cells.
Innovations in Tissue Engineering
Tissue engineering plays an important role in biomaterials research. It is gaining immense popularity for developing biological substitutes to maintain, restore, or improve tissue function. For example, in June 2023, OrganaBio announced the introduction of NeoPAC placenta and umbilical cord tissues that are specifically designed to accelerate the progress of regenerative medicine and cell therapy. Moreover, by providing both Research Use Only (RUO) and clinical-grade tissues, OrganaBio encourages researchers to tap into the potential of birth tissues, thereby enabling the development of innovative therapies to address numerous medical conditions. Apart from this, the rising demand for novel scaffolds that are materials engineered to cause desirable cellular interactions to facilitate the formation of new tissues is also elevating the market. For instance, in June 2023, 3DBioFibR, one of the leading innovators in tissue engineering, released two new collagen fiber products, namely CollaFibR 3D and μCollaFibR scaffold. These variants offer significant benefits for tissue culture and tissue engineering applications. Additionally, the elevating investments in R&D activities and research facilities by various organizations to enable the engineering of more structurally and functionally accurate tissues are contributing to the biomaterials market revenue. For example, in January 2023, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) established the Center for Biomedical Engineering Technology Acceleration (BETA Center), a new intramural research program to accelerate the validation, development, and dissemination of cutting-edge technologies. The center focuses on several areas, such as biosensing, engineered and synthetic biology, biomedical imaging, nanomaterials and biomaterials, etc.
Growing Applications in Wound Dressings
The rising adoption of biomaterials in advanced wound dressings, as they help in improving the healing process and outcomes for numerous types of wounds, including acute and chronic injuries, is acting as a significant growth-inducing factor. Besides this, key players are developing sustainable materials for wound care. For example, in March 2024, a team of scientists at the Institute of Advanced Study in Science and Technology (IASST), under the Department of Science and Technology, introduced an eco-friendly wound dressing material made using banana fibers. Moreover, all the materials utilized in creating this innovative dressing material are locally available and natural, making the manufacturing process cost-effective, simple, and non-toxic. Apart from this, the increasing inclination towards bio-material-based wound dressings is elevating the biomaterials market prices. They can be produced from various materials, including foams, hydrogels, films, etc., that are often imbued with bioactive substances like antimicrobial agents to reduce infection and promote tissue regeneration. For instance, in May 2022, Amferia AB, a Swedish medical device startup, was granted a foundational patent by the U.S. Patent and Trademark Office (USPTO) for an antimicrobial material based on an amphiphilic antimicrobial hydrogel. In line with this, in June 2023, according to the findings published in the Journal of Biomaterials Advances, a team of researchers from Queen's University of Belfast designed a 3D printed bandage, also called a scaffold, which presents an innovative method of treatment to heal diabetic foot ulcers (DFUs).
Currently, metallic biomaterial accounts for the largest market share
The growth in this segmentation is driven due to exceptional strength, optimal durability, and enhanced biocompatibility exhibited by metallic biomaterials. Consequently, they find extensive load-bearing applications, including dental implants, orthopedic implants, cardiovascular devices, etc. For instance, in April 2024, Boston Micro Fabrication (BMF) announced the U.S. Food and Drug Administration (FDA) clearance for its innovative UltraThineer material. Moreover, several metals, such as stainless steel, titanium, cobalt-chromium alloys, etc., are widely used, owing to their superior mechanical properties that ensure longevity and resilience under the stress of bodily movements. For example, in January 2022, according to the journal Colloids and Surfaces A, researchers efficiently modified a TC26 alloy with nanoporous TiO2 to enhance the osseointegration and bioactivity of artificial implants. In addition to this, in June 2023, Technopolis Moscow SEZ announced the production of titanium implants. As a result, the increasing product applications will continue to drive the metallic biomaterials market demand in the coming years.
Durable ceramic, metallic, and polymer-based materials are essential for joint replacements and bone repair. Moreover, they are adopted in the manufacturing of reconstructive devices that require high compatibility and strength with oral tissues. Apart from this, key areas, including neurology and cardiology, require biomaterials for neural implants, brain-machine interfaces, stents, pacemakers, etc. For instance, in February 2022, Researchers at the Lundquist Institute for Biomedical Innovation, Penn State, and the University of California Los Angeles developed novel biomaterials to promote new blood vessels and target post-stroke immune responses. According to the biomaterials market statistics, the other category encompasses additional applications like drug delivery systems and ophthalmology, where biomaterials offer tailored solutions for implants and controlled medication release, respectively.
North America currently dominates the global market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest biomaterials market share.
The favorable regulatory environment in North America, particularly the role of the U.S. Food and Drug Administration (FDA), which supports the rapid approval and development of new biomaterials and medical devices, is fueling the regional market. For example, in November 2019, DiFusion Inc. received FDA approval for its Xiphos-ZF spinal interbody device, which is based on a different biomaterial Zfuze, a combination of titanium and poly-ether-ether-ketone. Additionally, in October 2023, Dimension Inx, one of the biomaterials platform companies, announced the FDA approval of CMFlex, the first 3D-printed regenerative bone graft product. Moreover, the growing number of ambulatory surgical centers (ASCs) that perform spinal surgeries is acting as another significant growth-inducing factor. For instance, in February 2023, according to Becker's Healthcare data showcased that more than 183 ASCs in the United States perform minimally invasive spine surgery (MISS). Apart from this, the inflating popularity of cosmetic surgeries is further stimulating the regional market. In addition, the launch of initiatives undertaken by several public and private organizations, including the National Science Foundation and the National Institute of Standards and Technology, which provide assistance pertaining to biomaterials usage, is expected to fuel the market in North America over the forecasted period.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major biomaterials market companies have also been provided. Some of the key players in the market include: